KR102688415B1 - 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물 - Google Patents

표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물 Download PDF

Info

Publication number
KR102688415B1
KR102688415B1 KR1020207005448A KR20207005448A KR102688415B1 KR 102688415 B1 KR102688415 B1 KR 102688415B1 KR 1020207005448 A KR1020207005448 A KR 1020207005448A KR 20207005448 A KR20207005448 A KR 20207005448A KR 102688415 B1 KR102688415 B1 KR 102688415B1
Authority
KR
South Korea
Prior art keywords
minutes
subject
vascular
radiation
tpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005448A
Other languages
English (en)
Korean (ko)
Other versions
KR20200059213A (ko
Inventor
게리 아이헨바움
알프레드 토넬리
Original Assignee
잔센파마슈티카엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 잔센파마슈티카엔.브이. filed Critical 잔센파마슈티카엔.브이.
Publication of KR20200059213A publication Critical patent/KR20200059213A/ko
Application granted granted Critical
Publication of KR102688415B1 publication Critical patent/KR102688415B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
KR1020207005448A 2017-07-26 2018-07-26 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물 Active KR102688415B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762537049P 2017-07-26 2017-07-26
US62/537,049 2017-07-26
PCT/US2018/043821 WO2019023418A1 (en) 2017-07-26 2018-07-26 METHODS FOR PROTECTING VASCULAR INTEGRITY INDUCED BY TARGETED RADIOTHERAPY

Publications (2)

Publication Number Publication Date
KR20200059213A KR20200059213A (ko) 2020-05-28
KR102688415B1 true KR102688415B1 (ko) 2024-07-24

Family

ID=63165522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005448A Active KR102688415B1 (ko) 2017-07-26 2018-07-26 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물

Country Status (11)

Country Link
US (1) US12251424B2 (enExample)
EP (1) EP3658191A1 (enExample)
JP (1) JP7481252B2 (enExample)
KR (1) KR102688415B1 (enExample)
CN (1) CN111432845B (enExample)
AU (1) AU2018306329B8 (enExample)
BR (1) BR112020001367A2 (enExample)
CA (1) CA3070442A1 (enExample)
IL (1) IL272213A (enExample)
PH (1) PH12020500166A1 (enExample)
WO (1) WO2019023418A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54820A (fr) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
EP4525907A2 (en) * 2022-05-20 2025-03-26 JANSSEN Pharmaceutica NV Methods for mitigating lung injury in conjunction with exposure to radiation and/or radiation or radiomimetic treatments
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
WO2025002113A1 (zh) * 2023-06-26 2025-01-02 上海济煜医药科技有限公司 一种人血小板生成素受体激动剂的融合蛋白

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100625708B1 (ko) * 1996-12-11 2006-09-20 글락소 그룹 리미티드 수용체에 결합하는 펩티드 및 화합물
US20080119384A1 (en) * 2004-08-16 2008-05-22 Yurkow Edward J Use of TPO peptide compounds and pharmaceutical compostions in the treatment of anemia
JP2014097958A (ja) * 2012-11-15 2014-05-29 Hirosaki Univ 放射線被ばく治療剤及び放射線被ばく治療方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
CN1966520B (zh) 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1542714T3 (da) 2002-09-18 2014-05-26 Janssen Pharmaceuticals Inc Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller
RS20060141A (sr) 2003-08-28 2008-08-07 Ortho-Mcneil Pharmaceutical Inc., Peptidi i jedinjenja koja se vežu za receptor
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
PT1984014E (pt) 2006-02-14 2014-11-13 Janssen Pharmaceutica Nv Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia
CN100391474C (zh) * 2006-06-13 2008-06-04 卢建军 用于治疗血小板减少的注射用药物
JP2010511631A (ja) 2006-12-01 2010-04-15 ステイテジックス・インコーポレイテッド トロンボポエチン擬態物
WO2009114725A2 (en) 2008-03-12 2009-09-17 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
KR20110015448A (ko) 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 ｔｐｏ 모방 펩티드
MX2011008936A (es) 2009-02-24 2011-09-21 Alexion Pharma Inc Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
JP2012250880A (ja) 2011-06-03 2012-12-20 Semiconductor Energy Lab Co Ltd グラフェン、蓄電装置および電気機器
US20140047572A1 (en) 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US20140051631A1 (en) 2012-08-17 2014-02-20 Francoise Porteu Pharmaceutical composition comprising tpo or an agonist of the tpo receptor
US20200237872A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100625708B1 (ko) * 1996-12-11 2006-09-20 글락소 그룹 리미티드 수용체에 결합하는 펩티드 및 화합물
US20080119384A1 (en) * 2004-08-16 2008-05-22 Yurkow Edward J Use of TPO peptide compounds and pharmaceutical compostions in the treatment of anemia
JP2014097958A (ja) * 2012-11-15 2014-05-29 Hirosaki Univ 放射線被ばく治療剤及び放射線被ばく治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Qiaoqiao Li et al., Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications, Radiotherapy and Oncology(2014), vol. 112*

Also Published As

Publication number Publication date
AU2018306329B2 (en) 2024-09-19
JP7481252B2 (ja) 2024-05-10
KR20200059213A (ko) 2020-05-28
US20200164039A1 (en) 2020-05-28
CA3070442A1 (en) 2019-01-31
JP2020528903A (ja) 2020-10-01
EP3658191A1 (en) 2020-06-03
AU2018306329B8 (en) 2025-02-20
BR112020001367A2 (pt) 2020-08-11
IL272213A (en) 2020-03-31
AU2018306329A1 (en) 2020-02-13
PH12020500166A1 (en) 2020-09-14
WO2019023418A1 (en) 2019-01-31
US12251424B2 (en) 2025-03-18
CN111432845A (zh) 2020-07-17
CN111432845B (zh) 2024-02-06
AU2018306329A8 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
Wu et al. Near-infrared fluorescence imaging-guided focused ultrasound-mediated therapy against Rheumatoid Arthritis by MTX-ICG-loaded iRGD-modified echogenic liposomes
AU2018306329B8 (en) Methods of protecting vascular integrity induced by targeted radiation therapy
Alphandéry Glioblastoma treatments: an account of recent industrial developments
Chanda et al. Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nanoplatform for computer tomography theranostics
Palmowski et al. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions
US20220168392A1 (en) Methods of Enhancing Protection Against Organ and Vascular Injury, Hematopoietic Recovery and Survival in Response to Total Body Radiation/Chemical Exposure
JP2022523663A5 (enExample)
KR20210141460A (ko) 방사선 및/또는 방사선 모방체 치료와 함께 간 손상을 완화하고 간 비대, 재생 및 세포 생착을 촉진하는 방법
KR102103701B1 (ko) 전립선암 치료용 항-알파-ｖ 인테그린 항체
US20070010438A1 (en) Tumor treatment using beta-sheet peptides and radiotherapy
ES2854298T3 (es) Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1
JP2009507777A (ja) ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
US20230233705A1 (en) Gold nanoparticle-containing medicine
HK40033362A (en) Methods of protecting vascular integrity induced by targeted radiation therapy
US20250312417A1 (en) Methods for Mitigating Lung Injury in Conjunction with Exposure to Radiation and/or Radiation or Radiomimetic Treatments
EP0692259A2 (en) Use of HCG-specific antibody for the treatment of brain neoplasms
Gan et al. A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
Werahera et al. 575: Proliferative Tumor Doubling Times of Prostatic Carcinoma Measured by in Vivo Bromodeoxyuridine (BRDU) Labeling and Flow Cytometric Analysis
Ozzello Kari Cantell, 3 Roberto L. Ceriani, 2 and David V. Habif, Sr. 1 1 College of Physicians and Surgeons, Columbia University

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210325

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230906

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240307

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230906

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20240307

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20231103

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240627

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240722

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240722

End annual number: 3

Start annual number: 1

PG1601 Publication of registration